To include your compound in the COVID-19 Resource Center, submit it here.

CBER sowing worries about an exodus

From senior management to review staff, employees at FDA's Center for Biologics Evaluation and Research are warning that the CBER-CDER reorganization leaves them with the short end of the stick and are suggesting that a number of CBER reviewers will be looking for new jobs before or soon after they move to the Center for Drug Evaluation and Research.

CBER leadership also has suggested that the transfer could erode their ability to review the products that will remain in their purview.

The warnings don't appear to be resonating with biopharmaceutical companies or regulatory specialists, who say they are willing to live with short-term disruption

Read the full 1022 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE